Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors

Abstract

This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: wherein: Cy is independently a cyclyl group; Qis independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; Jis independently a covalent bond or —C(═; O)—; Jis independently —C(═O)— or —S(═O)—; Qis independently an acid leader group; wherein: Cy is independently: Ccarbocyclyl, Cheterocyclyl, or Caryl; and is optionally substituted; Qis independently: a covalent bond; Calkylene; or Calkylene-X—Calkylene, —X—Calkylene, or Calkylene-X—, wherein X is —O— or —S—; and is optionally substituted; Qis independently: Calkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Qis independently: Carylene; Carylene-Calkylene; Calkylene-Carylene; or, Calkylene-Carylene-Calkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.